# Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease

> **NCT03186989** · PHASE1 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 46 (actual)

## Conditions studied

- Mild Alzheimer's Disease

## Interventions

- **DRUG:** IONIS MAPTRx
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03186989
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-12
- **Primary completion:** 2022-05-12
- **Final completion:** 2022-05-12
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03186989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03186989, "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03186989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*